Cepheid  

(Public, NASDAQ:CPHD)   Watch this stock  
Find more results for Robert Easton�
55.01
0.00 (0.00%)
Apr 20 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 36.94 - 60.00
Open     -
Vol / Avg. 0.00/433,112.00
Mkt cap 3.93B
P/E     -
Div/yield     -
EPS -0.71
Shares 71.27M
Beta 0.95
Inst. own 101%
Apr 28, 2015
Cepheid Annual Shareholders Meeting - 4:00PM EDT - Add to calendar
Apr 23, 2015
Q1 2015 Cepheid Earnings Call - 5:00PM EDT - Add to calendar
Apr 23, 2015
Q1 2015 Cepheid Earnings Release - 4:00PM EDT - Add to calendar
Mar 4, 2015
Cepheid at Raymond James Institutional Investors Conference
Mar 3, 2015
Cepheid at Cowen Health Care Conference
Jan 29, 2015
Q4 2014 Cepheid Earnings Call - Webcast
Jan 29, 2015
Q4 2014 Cepheid Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -18.07% -10.67%
Operating margin -14.30% -7.25%
EBITD margin - 3.70%
Return on average assets -12.22% -8.44%
Return on average equity -26.63% -15.68%
Employees 1,400 -
CDP Score - -

Address

904 Caribbean Drive
SUNNYVALE, CA 94089
United States - Map
+1-408-5414191 (Phone)
+1-408-5414192 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Cepheid is a molecular diagnostics company that develops, manufactures and markets fully-integrated systems for testing in the Clinical and Non-Clinical markets. The Company�s systems enable molecular testing for organisms and genetic-based diseases by automating laboratory procedures. Its primary offering is the GeneXpert system, which integrates sample preparation in addition to DNA amplification and detection. The GeneXpert system is designed for a range of user types ranging from reference laboratories and hospital central laboratories to satellite testing locations, such as emergency departments and intensive care units within hospitals as well as physician offices and other alternate site laboratories. The Company also offers the SmartCycler system, which integrates DNA amplification and detection to allow analysis of a sample. As of December 31, 2013, it had approximately 1,200 full-time equivalent employees across the world.

Officers and directors

John L. Bishop Chairman of the Board, Chief Executive Officer
Age: 70
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Ilan Daskal Chief Financial Officer, Executive Vice President
Age: 49
Bio & Compensation  - Reuters
Warren C. Kocmond Jr. Chief Operating Officer, Principal Operating Officer, Executive Vice President
Age: 55
Bio & Compensation  - Reuters
David H. Persing M.D., Ph.D. Executive Vice President, Chief Medical and Technology Officer, Director
Bio & Compensation  - Reuters
Joseph H. Smith Executive Vice President - Corporate Development, General Counsel
Age: 70
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Peter Farrell Executive Vice President - International Commercial Operations
Age: 50
Bio & Compensation  - Reuters
Michael Fitzgerald Executive Vice President, Global Human Resources
Age: 55
Bio & Compensation  - Reuters
Kerry J. Flom Ph.D. Executive Vice President, Chief Regulatory Officer
Age: 63
Bio & Compensation  - Reuters
Daniel E. Madden Vice President, Corporate Controller
Age: 47
Bio & Compensation  - Reuters
Cristina H. Kepner Lead Independent Director
Age: 69
Bio & Compensation  - Reuters